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Abstract  
Objectives: Anti-tumor necrosis factor alpha (TNFα) agents are generally well tolerated, yet they can be 
associated with serious adverse events (SAEs) in a minority of patients. We examined the incidence of SAEs 
in a pediatric referral center for chronic rheumatologic and gastroenterological inflammatory disorders. 
Methods: Retrospective analysis of SAEs occurred during treatment with anti-TNFα agents in patients with 
juvenile idiopathic arthritis (JIA, n=78) and pediatric-onset inflammatory bowel diseases (IBD, n=105). Only 
SAEs grade 3 to 5 according to the Common Terminology Criteria for Adverse Events version 4.03 and/or 
requiring definitive therapy discontinuation were reported.  
Results: Total anti-TNFα exposure was 390.5 patient-years (PYs). The overall incidence rate of SAEs for 
etanercept was 4.14/100-PYs. Four patients developed uveitis, two had anxiety disorders, one had a serious 
zoster infection, and one developed TNFα antagonist–induced lupus-like syndrome (TAILS). The overall 
incidence rate of SAEs for infliximab was 22.49/100-PYs. The most common SAEs were anaphylactoid 
reactions (n=18), followed by infectious events (n=9) and TAILS (n=3). The overall incidence rate of SAEs 
for adalimumab was 4.71/100-PYs (two infectious SAEs). No malignancies or deaths were observed. A 
greater incidence rate of infectious SAEs was observed in IBD patients receiving infliximab compared to JIA 
patients receiving etanercept (8.11 vs 0.52 per 100 PYs). 
Conclusions: Anti-TNFα therapy was generally well tolerated. SAEs leading to anti-TNFα discontinuation 
were rare and non-fatal. Infliximab was associated with the highest incidence of SAEs. Infectious SAEs were 
more frequently observed in IBD patients treated with infliximab than in JIA patients receiving etanercept. 
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Key Points 
 
Serious adverse events (SAEs) associated with anti-TNFα therapy in children with chronic inflammatory 
disorders were rare and non-fatal; most SAEs regressed after drug withdrawal. 
 
Infliximab was associated with the highest incidence of SAEs, mostly anaphylactoid reactions. 
 
Infectious SAEs were more frequent in patients with inflammatory bowel disease treated with infliximab 
than in patients with juvenile idiopathic arthritis receiving etanercept. 
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1 INTRODUCTION 
 
Juvenile idiopathic arthritis (JIA) and pediatric-onset Inflammatory Bowel Diseases (IBD) are chronic 
disorders that pose a significant toll in terms of morbidity and quality of life in affected children [1,2]. While 
a definitive cure is not yet available, achieving disease remission can lead to normal quality of life and 
prevent complications [3,4]. The advent of biologic anti-tumor necrosis factor alpha (TNFα) drugs in the late 
90s has led to a revolution in the therapeutic approach to these conditions, especially in patients refractory to 
other medications. The most commonly used anti-TNFα agents in pediatric patients are etanercept, a fusion 
protein combining TNFα receptor with the constant end of an IgG1 antibody; infliximab, a chimeric 
monoclonal antibody; and adalimumab, a fully human monoclonal antibody. Etanercept is approved for JIA, 
but has no therapeutic indication for IBD; adalimumab is approved for both JIA and IBD; infliximab is 
approved for IBD, but has been used off-label in JIA patients before etanercept and adalimumab approval. In 
2016, a new anti-TNFα, golimumab, was approved for polyarticular JIA. While these drugs have been 
shown to be generally cost-effective, concerns still exist on their safety, since their use has been associated 
with serious infectious [5], neoplastic [6], and immunologic disorders [7]. We examined the incidence of 
serious adverse events (SAEs) in a single pediatric referral center for chronic rheumatologic and 
gastroenterological inflammatory disorders. 
 
2 METHODS 
 
We retrospectively reviewed all patients with a diagnosis of JIA or IBD before 18 years of age seen at the 
Institute for Maternal and Child Health IRCCS “Burlo Garofolo” in Trieste, Italy, between June 2001 and 
February 2016. We included patients <18 years of age, as well as young adults (age 18-30 years) with 
pediatric-onset diseases who were continuing to be treated at center. Institutional review board approval is 
not required for retrospective studies at our institution. Only patients treated with anti-TNFα agents 
(etanercept, infliximab, adalimumab) were selected. The following data were collected: gender, age at 
disease onset, age at anti-TNFα start, concurrent medications (immunosuppressants and corticosteroids), 
number and type of SAEs, which were defined as adverse events requiring definitive therapy discontinuation 
 5 
and/or adverse events classified as severe, life threatening, or fatal (grade 3 to 5) according to the Common 
Terminology Criteria for Adverse Events (CTCAE), version 4.03 [8]. All patients underwent infectious 
disease screening prior to starting anti-TNFα therapy. ‘Drug exposure’ refers to time between the first drug 
administration and the moment of discontinuation or the last available follow-up visit. Continuous data are 
expressed as medians and interquartile ranges (IQR), and categorical data are expressed as absolute 
frequencies and percentages. Incidence rates are reported as events per 100 patient-years (PYs) and 95% 
confidence intervals (95% CI). Confidence intervals are calculated with mid-p exact test. Comparisons of 
incidence rates were performed by means of Fisher’s exact test. The statistical test was two-sided and a p-
value of less than 0.05 was considered as statistically significant. The Bonferroni correction was applied for 
multiple comparisons, multiplying the uncorrected p-values by the number of comparisons made. Relative 
risk (RR) was calculated as conditional maximum likelihood estimate of rate ratio with mid-p exact test. 
 
3 RESULTS 
 
We identified 183 patients (78 with JIA and 105 with IBD) who were exposed to anti-TNFα drugs; their 
characteristics and exposure to anti-TNFα drugs are summarized in table 1. Nine patients with JIA and 13 
patients with pediatric-onset IBD were aged 18-30 at treatment start. During follow-up, 34 patients (18.6%) 
experienced at least one SAE. Numbers and incidence rates of SAEs are summarized in table 2. No cases of 
tuberculosis, malignancies, or deaths were observed for any of the anti-TNFα drugs. 
 
3.1 SAEs related to etanercept therapy 
 
Etanercept was used only in patients with JIA. A total of 8 SAEs were recorded, for an overall incidence rate 
of 4.14/100-PYs (95% CI 1.97 – 7.85) (table 2). Four patients developed uveitis: all of them were female, 
with early-onset (<3 years of age), extended oligoarticular JIA with positive anti-nuclear antibody (ANA). 
Median treatment duration before uveitis onset was 14 months, with two patients experiencing uveitis in the 
first three months of treatment. Only one patient had a history of previous uveitis. Two patients continued to 
have relapsing uveitis after etanercept discontinuation. Two patients developed an anxiety disorder with 
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panic attacks, after 8 and 12 months of drug exposure, respectively, which resolved after drug 
discontinuation. One patient had a serious herpes zoster infection. TNFα antagonist–induced lupus-like 
syndrome (TAILS) developed in a 12-year-old boy with rheumatoid factor (RF)-negative polyarticular JIA, 
as reported elsewhere [9].  
 
3.2 SAEs related to infliximab therapy 
 
Infliximab was used both in JIA and in IBD patients. A total of 30 SAEs were recorded in patients receiving 
infliximab, for an overall incidence rate of 22.49/100-PYs (table 2). The most common SAEs were 
anaphylactoid reactions to drug infusion. Median drug exposure before anaphylactoid reaction occurrence 
was 1.5 months (IQR 0.5 – 13), with eight reactions occurring at the second infliximab infusion. Nine 
infectious SAEs occurred in six IBD patients treated with infliximab (one complicated pneumonia, one 
scrotal abscess, one cytomegalovirus infection; three patients had an infectious SAEs twice: two patients had 
two episodes of sepsis each, one patient had two episodes of peritonsillar abscesses). In six cases patients 
were on concomitant therapy with another immunosuppressive drug. Median exposure to infliximab before 
infection occurrence was 3.5 months (IQR 1.5 – 5.5).  
Three patients with ulcerative colitis developed TAILS after a median drug exposure of 7 months [10]. A 
boy developed cutaneous leukocytoclastic vasculitis, mild arthritis, microscopic hematuria, and proteinuria, 
with normal complement levels and negative autoantibodies. A girl developed malar rash with transient 
ANA positivity. The third patient was a girl who developed fever, diffuse pyoderma, malar rash, laryngitis 
and pulmonary infiltrates, with markedly increased inflammatory markers, normal complement levels and no 
evidence of autoantibodies. The first two patients did not require specific treatment beyond drug withdrawal, 
which led to resolution of all symptoms except for a persisting mild proteinuria in the first patient, while the 
third patient required treatment with intravenous steroids and antibiotics.  
 
3.3 SAEs related to adalimumab therapy 
 
A total of 3 SAEs were recorded in JIA and IBD patients receiving adalimumab, for an overall incidence rate 
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of 4.71/100-PYs (Table 2). Two patients experienced recurrent herpetic infections. The third patient, a 14-
year-old girl with polyarticular JIA, discontinued treatment because of fatigue, myalgia, nausea and 
epigastric pain after adalimumab injections.  
 
3.4 Incidence rates comparisons  
 
Patients treated with infliximab had a higher incidence of SAEs compared to patients treated with etanercept 
(RR 5.44, 95% CI 2.57 – 12-64, p<0.01) and adalimumab (RR 4.77, 95% CI 1.62 – 19.70, p=0.01); no 
differences were observed between etanercept and adalimumab (RR 0.88, 95% CI 0.24 – 4.09, p=NS). IBD 
patients treated with infliximab experienced more infectious SAEs than JIA patients treated with etanercept 
(RR 15.69, CI 95% 2.58-346.80, p < 0.001).  
 
4 DISCUSSION 
 
There are several limitations to our study, including the relatively small size of our cohort and the 
retrospective design; in addition, follow-up was not equally long for every anti-TNFα drug. Nevertheless, 
keeping in mind these limitations, our data confirm the long-term tolerability of anti-TNFα therapy for 
pediatric-onset inflammatory disorders and the very low risk of persistent SAEs. These results are in line 
with previous studies on safety of anti-TNFα drugs in children (table 3) [11–23]. In our experience, 
etanercept was associated with a low incidence of SAEs, comparable to that of previous reports. Notably, 
most SAEs associated with etanercept in our cohort were immune-mediated (uveitis, TAILS), while 
infectious SAEs were uncommon. Data from published studies on uveitis occurrence in JIA patients 
receiving etanercept are contrasting. In fact, while uveitis is a know complication of JIA, etanercept has been 
postulated to be associated with increased risk of ocular inflammation [24]. However, other studies 
suggested a role for methotrexate discontinuation rather than a direct association of etanercept [17]. In our 
experience, uveitis occurred only in children with pre-existing risk factors for uveitis. Etanercept was the 
only drug associated with neuropsychiatric SAEs, which were the second most common reason for drug 
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discontinuation. This association has been already described in previous studies [18], yet causality seems 
difficult to prove. Notably, in our patients neuropsychiatric symptoms resolved after drug discontinuation.  
Similarly to data from previous reports [12,15], infliximab was associated with the highest incidence of 
SAEs in our cohort. Anaphylactoid reactions were equally present in JIA and IBD patients, most commonly 
at infliximab second infusion, while infections and autoimmune disorders occurred only in patients with 
IBD, possibly due to the small number of JIA patients exposed to infliximab. Notably, a greater incidence 
rate of infectious SAEs in IBD patients treated with infliximab was observed as compared to JIA patients 
treated with etanercept (8.11 vs 0.52 per 100 PYs). While a substantial heterogeneity exist among previous 
studies (table 3), this trend seems in accordance with results from comprehensive meta-analyses on anti-
TNFα safety in children. A recent meta-analysis on etanercept safety in JIA reported a low number of 
infectious SAEs (1.2 per 100 PYs) [25]. On the other hand, results from a meta-analysis on the risk of severe 
infections in children receiving anti-TNFα for IBD identified an overall risk of 3.52 per 100 PYs [26]. 
Several explanations may exist for this difference, including the different pharmacodynamic properties of 
etanercept [27], intrinsic risk factors associated with the disease itself (e.g. loss of gut barrier in IBD 
patients), as well as the greater use of concomitant immunosuppressants in IBD patients in our cohort. 
Three patients with IBD, all treated with infliximab, and one patient with JIA, treated with etanercept 
developed TAILS. TAILS is a rare condition with an incidence of less than 1% [28,29]; specific criteria for 
the diagnosis of TAILS have not been established yet. The most accepted diagnostic criteria include a 
temporal relationship between clinical manifestations and anti-TNFα therapy, at least one serologic and one 
non-serologic American College of Rheumatology criteria for systemic lupus erythematous [15]. Although 
two of our patients lacked the serologic criteria, the clinical manifestations and the temporal relationship 
with anti-TNFα therapy clearly suggested a diagnosis of TAILS, which occurred, in our experience, more 
frequently than in other studies, especially in IBD patients treated with infliximab.  
Most SAEs resolved with treatment discontinuation: only two uveitis, occurred with etanercept, and one 
TAILS, occurred with infliximab, persisted. No patients died during the follow-up period and we did not 
observe malignancies, yet the follow-up was too short to draw any conclusion. Nevertheless, data from larger 
studies do not seem to support an increased risk of malignancies in children receiving anti-TNFα agents 
[17,23,26].  
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5 CONCLUSIONS 
 
Despite the small number of patients in our cohort, our data confirm that treatment with anti-TNFα agents in 
patients with JIA and pediatric-onset IBD is generally well tolerated. A low incidence of SAE was observed, 
and even when anti-TNFα discontinuation was necessary, SAEs were mostly not persistent and non-fatal. 
Infliximab seems to be the anti-TNFα agent associated with the greatest risk of SAEs in both JIA and IBD 
patients. Immunologic treatment-related SAEs represent an important subgroup of SAEs in these patients. In 
particular, the possibility of a specific anti-TNFα-related lupus-like syndrome, i.e. TAILS, should be kept in 
mind, since its clinical presentation may be protean, and it may benefit from drug discontinuation. Severe 
infections may occur more frequently in IBD patients receiving infliximab as compared to JIA patients 
receiving etanercept, nevertheless all drugs in this class are associated with an increased risk of severe 
infections, therefore prompt medical evaluation is always mandatory in case of signs and symptoms 
suggesting an infectious complication. 
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Table 1. Characteristics of the patients included in the study and exposure to anti-TNFα drugs.  
 
Total 
(N = 183) 
JIA 
(N = 78) 
IBD 
(N = 105) 
Gender, N (%) Male 
Female 
72 (39.3) 
111 (60.7) 
 21 (26.9) 
57 (73.1) 
51 (48.6) 
54 (51.4) 
Age at disease onset, median (IQR) 9.90 (5.01 – 12.85) 5.11 (2.03 – 8.98) 11.18 (9.37 – 13.67) 
Age at first anti-TNFα , median 
(IQR) 
12.94 (9.58 – 15.91) 10.59 (5.68 – 14.56) 13.47  (11.47 – 16.53) 
Disease duration before anti-TNFα  
start (years), median (IQR) 
1.84 (0.66 – 4.50) 3.09 (1.34 – 6.30) 1.17 (0.54 – 3.11) 
Disease categories, N (%) 
 
 
 
 
 Polyarticular           
• RF-positive 
• RF-negative 
Oligoarticular         
• Persistent         
• Extended 
Systemic         
Psoriatic 
 
ANA-positive                   
ANA-negative              
34 (43.6) 
4 (5.1) 
30 (38.5) 
35 (44.9) 
22 (28.2) 
13 (16.7) 
8 (10.2) 
1 (1.3) 
 
37 (47.4) 
41 (52.6) 
Crohn’s disease       71 (67.6) 
Ulcerative colitis     34 (32.4) 
 
Anti-TNFα  therapy, N patients (%) 
Infliximab  
Etanercept 
Adalimumab  
 
121 (66.1) 
64 (35) 
48 (26.2) 
 
18 (23.1) 
64 (82.1) 
28 (35.9) 
 
103 (98.1) 
- 
20 (19)  
Drug exposure, PYs 
Infliximab  
Etanercept 
Adalimumab 
Total 
 
133.42 
193.42 
63.67 
390.51 
 
22.46 
193.42 
45.75 
261.63 
 
110.96 
- 
17.92 
128.88 
Anti-TNFα  drugs per patient, N (%) 
One anti-TNFα  
Two anti-TNFα 
Three anti-TNFα 
 
138 (75.4) 
40 (21.9) 
5 (2.7) 
 
51 (65.4) 
22 (28.2) 
5 (6.4) 
 
87 (82.9) 
18 (17.1) 
-  
 
Abbreviations: TNF, Tumor Necrosis Factor; JIA, Juvenile Idiopathic Arthritis; IBD, Inflammatory Bowel 
Disease; IQR, interquartile ranges; RF, Rheumatoid Factor; ANA, Anti-Nuclear Antibody; PYs, Patient-
years. 
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Table 2. Absolute number and specific incidence rates of SAEs. 
Abbreviations: SAEs, Serious Adverse Events; TNF, Tumor Necrosis Factor; PYs, Patient-years; CI, Confidence 
interval; JIA, Juvenile idiopathic arthritis; IBD, Inflammatory bowel diseases; IQR, interquartile range. 
 ETANERCEPT INFLIXIMAB ADALIMUMAB 
Type of SAEs SAEs,  
N 
 SAEs/100-PYs  
(95% CI) 
SAEs
, N 
SAEs/100-PYs  
(95% CI) 
SAEs
, N 
SAEs/100-PYs  
(95% CI) 
Uveitis JIA 4 2.07 (0.66-4.99) 0 0 (0-12.49) 0 0 (0-6.34) 
IBD - - 0 0 (0-2.66) 0 0 (0-15.39) 
JIA+IBD - - 0 0 (0-2.22) 0 0 (0-4.60) 
Psychiatric disorders  JIA 2 1.03 (0.17-3.42) 0 0 (0-12.49) 0 0 (0-6.34) 
 IBD - - 0 0 (0-2.66) 0 0 (0-15.39) 
 JIA+IBD - - 0 0 (0-2.22) 0 0 (0-4.60) 
Infections JIA 1 0.52 (0.03-2.55) 0 0 (0-12.49) 1 2.19 (0.11-10.78) 
IBD - - 9 8.11 (3.96-14.88) 1 5.58 (0.28-27.52) 
JIA+IBD - - 9 6.75 (3.29-12.38) 2 3.14 (0.53-10.38) 
Immunologic disorders JIA 1 0.52 (0.03-2.55) 0 0 (0-12.49) 0 0 (0-6.34) 
 IBD - - 3 2.70 (0.69-7.36) 0 0 (0-15.39) 
 JIA+IBD - - 3 2.25 (0.57-6.12) 0 0 (0-4.60) 
Anaphylactoid reactions JIA 0 0 (0-1.54) 3 13.36 (3.40-36.35) 0 0 (0-6.34) 
IBD - - 15 13.52 (7.85-21.80) 0 0 (0-15.39) 
JIA+IBD - - 18 13.49 (8.25-20.91) 0 0 (0-4.60) 
Gastrointestinal disorders JIA 0 0 (0-1.54) 0 0 (0-12.49) 1 2.19 (0.11-10.78) 
 IBD - - 0 0 (0-2.66) 0 0 (0-15.39) 
 JIA+IBD - - 0 0 (0-2.22) 1 1.57 (0.08-7.75) 
TOTAL JIA 8 4.14 (1.92-7.85) 3 13.36 (3.40-36.35) 2 4.37 (0.73-14.44) 
 IBD - - 27 24.33 (16.36-34.91) 1 5.58 (0.28-27.52) 
 JIA+IBD - - 30 22.49 (15.45-31.69) 3 4.71 (1.20-12.82) 
Median drug exposure before SAEs, 
months, median (IQR) 
 
19.5 (11-24) 
 
8.5 (1.5-15.5) 
 
12 (7.5-15) 
SAEs occurred with concomitant 
immunosuppressant therapy, N (%) 
  
1 (12.5) 
  
11 (36.7) 
 
0 (0) 
SAEs occurred with concomitant 
steroid therapy, N (%) 
 
0 (0) 
 
1 (3.3) 
 
0 (0) 
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Table 3. Studies on SAEs incidence in children treated with anti-TNFα drugs.  
 
First author and year 
of publication 
Dise
ase 
Type of 
study 
Patients  
(PYs) 
Drug Total 
SAEs 
/100 PYs 
Infectious 
SAEs 
/100-PYs 
Malignancies 
/100 PYs 
Deaths 
/100 
PYs 
Horneff 2004 [11] JIA PRO 322 (592) ETA 2.03 NA  NA NA 
Gerloni 2008 [12] JIA RETRO 68 (140) 
95 (258) 
INF 
ETA 
NA 
NA 
0.7 
0.7 
0 
0.4 
0 
0 
Prince 2009 [13] JIA PRO 146 (312) ETA 2.9 1.28 0 0 
Schmeling 2014 [14] JIA PRO 289 (435.7) ADA 2.5 0.2  0 0 
Tarkiainen 2015 [15] JIA RETRO  213 (710) 
214 (591)  
94 (188) 
ETA 
INF 
ADA 
11.4 
11.8 
10.1 
4.2 
3.4 
2.1 
0 
0 
0 
0.2 
0 
0 
Windschall 2015 [16] JIA PRO 1678 (2805) ETA 3.49 0.25 0.07 0 
Klotsche 2016 [17] JIA PRO 1414 (4461)  
320 (493) 
ETA 
ADA 
4.46 
4.67 
0.92  
0.41 
0.09  
0.27 
0.05  
0  
Verazza 2016 [18] JIA RETRO 1038 (NA) ETA NA 13a 2a 1a 
Baldassano 2013 [19] IBD PRO 2503 (4347) INF NA 4.88 NA NA 
Colletti 2013 [20] IBD PRO 2503 (4347) INF NA NA 0.09b NA 
Vahabnezhad 2014 [21] IBD RETRO  188 (NA) INF NA 1a 1a 0a 
Cameron 2015 [22] IBD RETRO 127 (NA) 
29 (NA) 
INF 
ADA 
NA 
NA 
6a 
2a 
0a 
0a 
0a 
0a 
Hyams 2017 [23] IBD PRO 5766 (24543) INF NA NA 0.04 NA 
 
a Data not available as SAEs/100-PYs. Data are reported as absolute number of SAEs.  
b Data only for lymphoma.   
Abbreviations: ADA, adalimumab; ETA, etanercept; INF, infliximab; IBD, Inflammatory bowel diseases; 
JIA, Juvenile idiopathic arthritis; CD, Crohn’s disease; SAEs, Serious adverse events; TNFα, Tumor necrosis 
factor alpha; NA, not available; PYs, patient-years; PRO, prospective; RETRO, retrospective.	
